Trials / Completed
CompletedNCT05346172
The Clareon PanOptix Trifocal IOL: Visual Outcomes and Patient Satisfaction
The Clareon PanOptix Trifocal IOL: A Study of Patient Satisfaction and Visual Performance
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (actual)
- Sponsor
- Research Insight LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This will be a single arm, open-label, prospective study of patient-reported outcomes of patients with bilateral implantation of the Panoptix or Panoptix Toric implant.
Detailed description
The PanOptix trifocal lens by Alcon was introduced in 2015 and is currently in use in over 70 countries. Its outcomes on the AcrySof platform are well documented and highly appealing to patients and clinicians.,, Clinicians no longer need to routinely target monovision or modified monovision to provide a range of vision. With the release of the Clareon material for this lens, questions remain about how the new lens material will influence patient satisfaction and uncorrected visual performance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | PanOptix or PanOptix Toric IOL | Patients who previously underwent cataract surgery with the PanOptix or PanOptix Toric IOL in both eyes. |
Timeline
- Start date
- 2022-06-17
- Primary completion
- 2023-03-10
- Completion
- 2023-03-10
- First posted
- 2022-04-26
- Last updated
- 2023-03-15
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05346172. Inclusion in this directory is not an endorsement.